Literature DB >> 16970019

Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation.

Joel J Heidelbaugh1, Michael Bruderly.   

Abstract

Cirrhosis and chronic liver failure are leading causes of morbidity and mortality in the United States, with the majority of preventable cases attributed to excessive alcohol consumption, viral hepatitis, or nonalcoholic fatty liver disease. Cirrhosis often is an indolent disease; most patients remain asymptomatic until the occurrence of decompensation, characterized by ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, or variceal bleeding from portal hypertension. Physical examination of patients with cirrhosis may reveal a variety of findings that necessitate a hepatic- or gastrointestinal-based work-up to determine the etiology. Some patients already may have had laboratory or radiographic tests that incidentally uncovered signs of cirrhosis and its comorbidities. No serologic or radiographic test can accurately diagnose cirrhosis. A significant correlation has been demonstrated between persistently elevated liver function tests and biopsy-proven underlying hepatic disease; thus, a more targeted serologic work-up is indicated in patients whose liver function test results are persistently abnormal. Unnecessary medications and surgical procedures should be avoided in patients with cirrhosis. Referral for liver biopsy should be considered only after a thorough, non-invasive serologic and radiographic evaluation has failed to confirm a diagnosis of cirrhosis; the benefit of biopsy outweighs the risk; and it is postulated that biopsy will have a favorable impact on the treatment of chronic liver disease.

Entities:  

Mesh:

Year:  2006        PMID: 16970019

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  90 in total

Review 1.  Implications of opioid analgesia for medically complicated patients.

Authors:  Howard Smith; Patricia Bruckenthal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  A comparison of the chemical and liver extract-induced hepatic differentiation of adipose derived stem cells.

Authors:  Truong Hai Nhung; Nguyen Hai Nam; Nguyen Thi Kim Nguyen; Huynh Nghia; Nguyen Van Thanh; Phan Kim Ngoc; Phuc Van Pham
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-08-15       Impact factor: 2.416

Review 3.  Stem cells for end stage liver disease: how far have we got?

Authors:  Stefania Lorenzini; Stefano Gitto; Elena Grandini; Pietro Andreone; Mauro Bernardi
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

Review 4.  Approach to clinical syndrome of jaundice and encephalopathy in tropics.

Authors:  Anil C Anand; Hitendra K Garg
Journal:  J Clin Exp Hepatol       Date:  2014-06-06

5.  Management of liver cirrhosis between primary care and specialists.

Authors:  Ignazio Grattagliano; Enzo Ubaldi; Leonilde Bonfrate; Piero Portincasa
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

6.  Obstetric Outcome in Women with Chronic Liver Disease.

Authors:  Pinky Jena; C N Sheela; Rao Preethi Venkatachala; Harshad Devarbhavi
Journal:  J Obstet Gynaecol India       Date:  2016-12-26

7.  Microcystin-LR in peripheral circulation worsens the prognosis partly through oxidative stress in patients with hepatocellular carcinoma.

Authors:  Feifei Lei; Xu Lei; Rugui Li; Huabing Tan
Journal:  Clin Exp Med       Date:  2019-03-12       Impact factor: 3.984

8.  KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.

Authors:  Yu-Shui Ma; Ting-Miao Wu; Bin Qian; Yu-Shan Liu; Hua Ding; Ming-Ming Fan; Ji-Bin Liu; Fei Yu; Hui-Min Wang; Yi Shi; Li-Peng Gu; Liu Li; Lin-Lin Tian; Pei-Yao Wang; Gao-Ren Wang; Zhi-Jun Wu; Qi-Fei Zou; Chang-Chun Ling; Da Fu
Journal:  J Cell Mol Med       Date:  2021-02-23       Impact factor: 5.310

9.  Model for End-Stage Liver Disease Underestimates Morbidity and Mortality in Patients with Ascites Undergoing Colectomy.

Authors:  Matthew M Fleming; Fangfang Liu; Yawei Zhang; Kevin Y Pei
Journal:  World J Surg       Date:  2018-10       Impact factor: 3.352

Review 10.  Quality of life in cirrhosis.

Authors:  Anthony Loria; Carey Escheik; N Lynn Gerber; Zobair M Younossi
Journal:  Curr Gastroenterol Rep       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.